GLP-1 Drugs and Cancer – Unexpected Survival Benefits in Colon Cancer Patients

December 20, 2025

Audio Overview

🎧

View Transcript

Drugs like Ozempic and Wegovy were developed to treat diabetes and obesity. But new research suggests they might have an unexpected benefit: dramatically improving survival in cancer patients.

A study from UC San Diego, published in Cancer Investigation in November 2025, analyzed more than 6,800 colon cancer patients across the University of California Health system. The findings were striking.

Patients taking GLP-1 medications were less than half as likely to die within five years compared to those not on the drugs. The numbers: 15.5 percent mortality for GLP-1 users versus 37.1 percent for non-users.

Now, this was an observational study, not a randomized trial. Patients taking GLP-1 drugs likely differ from non-users in ways that could affect outcomes. The researchers acknowledge this limitation.

But the magnitude of the difference—and growing laboratory evidence supporting it—has researchers calling for clinical trials to formally test whether GLP-1 drugs have direct anti-cancer effects.

Several biological mechanisms could explain the findings. GLP-1 drugs reduce systemic inflammation, which promotes cancer progression. They improve insulin sensitivity, and elevated insulin has been linked to tumor growth. They promote weight loss, and obesity is a known cancer risk factor. And laboratory studies suggest GLP-1 may directly inhibit cancer cell growth and induce cancer cell death.

Lead researcher Dr. Raphael Cuomo noted that the greatest benefit appeared in patients with BMI over 35, suggesting that the metabolic improvements from these drugs may be particularly important.

This research adds to a growing pattern of GLP-1 drugs showing benefits beyond their original purpose—from cardiovascular protection to kidney disease to now potentially cancer survival. We may be only beginning to understand what these medications can do.

An Unexpected Finding

When researchers study a medication long enough, they sometimes discover it does more than originally intended. Aspirin, developed as a pain reliever, turned out to reduce heart attack risk. Metformin, a diabetes drug, shows associations with reduced cancer incidence. Statins, designed to lower cholesterol, appear to have anti-inflammatory effects that extend beyond cardiovascular disease.

GLP-1 receptor agonists—the class of drugs that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—may be following this pattern. Developed for diabetes and later obesity, these medications are now showing associations with improved outcomes in conditions far removed from metabolic disease.

The latest surprise: dramatically improved survival in colon cancer patients.

The UC San Diego Study

Research published in Cancer Investigation in November 2025 examined outcomes in more than 6,800 colon cancer patients treated across the University of California Health system. The study, led by Dr. Raphael Cuomo, Associate Professor in the Department of Anesthesiology at UC San Diego School of Medicine and a member of the Moores Cancer Center, compared survival between patients who were taking GLP-1 medications and those who were not.

The difference was substantial.

Among patients taking GLP-1 drugs, the five-year mortality rate was 15.5 percent. Among those not taking these medications, it was 37.1 percent. In other words, GLP-1 users were less than half as likely to die within five years.

This is an observational study, which means patients weren’t randomly assigned to receive GLP-1 drugs or not. Those who happened to be taking these medications for diabetes or weight management formed one group; those who weren’t formed the comparison group. This design has important limitations—the groups likely differ in ways beyond just GLP-1 use.

But the magnitude of the survival difference, combined with biological plausibility and supporting laboratory research, has captured attention.

Why Might GLP-1 Drugs Affect Cancer?

Several mechanisms could explain an anti-cancer effect, and the research team highlighted multiple pathways.

Reduced inflammation: Chronic inflammation promotes cancer development and progression. GLP-1 drugs have documented anti-inflammatory effects, reducing circulating inflammatory markers. By dampening systemic inflammation, they could create an environment less conducive to tumor growth.

Improved insulin sensitivity: Elevated insulin levels have been linked to cancer promotion. Insulin acts as a growth factor, and many tumors have insulin receptors. GLP-1 drugs improve insulin sensitivity and reduce circulating insulin levels, potentially removing a growth signal for cancer cells.

Weight loss: Obesity is an established risk factor for multiple cancers, including colon cancer. The mechanisms are complex—involving inflammation, hormones, and metabolic factors—but the epidemiological link is clear. By promoting weight loss, GLP-1 drugs could reduce cancer risk through this pathway.

Direct cellular effects: Laboratory research suggests GLP-1 may have direct effects on cancer cells independent of metabolic changes. Studies have shown that GLP-1 receptor activation can inhibit cancer cell growth, induce apoptosis (programmed cell death), and alter the tumor microenvironment composition.

Notably, the UC San Diego study found that the greatest survival benefit appeared in patients with BMI exceeding 35. This suggests that the metabolic improvements these drugs provide may be particularly important, though it doesn’t rule out direct anti-cancer mechanisms.

Cautions and Limitations

The researchers were careful to acknowledge what their study does and doesn’t show.

“While these results are observational, they underscore an urgent need for clinical trials to test whether GLP-1 drugs can improve cancer survival rates,” Dr. Cuomo stated.

The observational nature is a significant limitation. Patients taking GLP-1 medications likely differ from non-users in multiple ways. They may have better access to healthcare, different baseline health status, or other characteristics that affect cancer outcomes. Statistical methods can partially adjust for these differences, but they can’t eliminate them entirely.

The study looked at a specific population—colon cancer patients within the UC Health system. Whether findings would generalize to other cancer types or other healthcare settings is unknown.

The mechanism remains uncertain. The correlation is clear, but whether GLP-1 drugs directly improve cancer survival, or whether their benefits are entirely mediated through metabolic improvements, requires further research to determine.

The Call for Clinical Trials

Observational data, no matter how compelling, can’t establish causation. The only way to definitively determine whether GLP-1 drugs improve cancer outcomes is through randomized controlled trials—studies where patients are randomly assigned to receive the treatment or a placebo.

Such trials present challenges. They require significant time and resources. There are ethical considerations in withholding potentially beneficial medications from cancer patients. And the patient populations (those with obesity or diabetes who would typically receive GLP-1 drugs versus cancer patients who might not) don’t perfectly overlap.

Despite these challenges, the strength of the observational signal is prompting serious discussion about designing appropriate trials. Given that millions of people are already taking these medications, understanding their full effects—beneficial and otherwise—is increasingly important.

Part of a Larger Pattern

The cancer findings add to an expanding list of conditions where GLP-1 drugs show unexpected benefits.

Cardiovascular protection has been documented in multiple large trials, leading to FDA approval of some GLP-1 drugs specifically for cardiovascular risk reduction in certain patients. Kidney disease progression slows in patients taking these medications. Liver fat decreases, with implications for fatty liver disease. Sleep apnea improves, likely related to weight loss. Some research suggests potential benefits for neurodegenerative conditions, though this remains preliminary.

The breadth of these effects suggests that the metabolic improvements these drugs provide—reduced inflammation, better glucose control, weight loss, improved insulin sensitivity—have systemic benefits that extend throughout the body. Cancer, fundamentally a disease of cellular dysfunction influenced by metabolic factors, may be responsive to these same improvements.

Implications for Practice

At this stage, the research doesn’t support prescribing GLP-1 drugs specifically to treat or prevent cancer. The evidence isn’t there yet, and these medications have their own considerations including side effects and cost.

But for patients already taking GLP-1 drugs for diabetes or obesity, the emerging evidence provides additional context about potential benefits. And for clinicians managing cancer patients who also have metabolic conditions, the data adds another factor to consider in treatment decisions.

For researchers, the findings point toward important questions deserving further investigation. Understanding whether the cancer association reflects direct effects, metabolic mediation, or some combination could inform both cancer treatment and the development of future therapies.

What We’re Watching

The intersection of metabolic health and cancer—sometimes called metabolic oncology—is an emerging field recognizing that how we process energy affects cancer risk and outcomes. GLP-1 drugs, by dramatically altering metabolism, offer a window into this relationship.

As more patients take these medications and longer-term data accumulates, we’ll learn more about their full spectrum of effects. Clinical trials specifically designed to test cancer-related benefits may eventually provide definitive answers.

For now, the UC San Diego findings represent another data point suggesting that GLP-1 drugs may be more than just weight loss medications—they may be broadly protective in ways we’re still discovering.

Sources

1. Cuomo R, et al. “GLP-1 Receptor Agonists and Mortality in Colon Cancer Patients.” Cancer Investigation. November 11, 2025.

2. UC San Diego Today. “GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients.” November 2025. https://today.ucsd.edu/story/glp-1-drugs-linked-to-dramatically-lower-death-rates-in-colon-cancer-patients